Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 306

1.

Assessing the Metabolomic Profile of Multiple Sclerosis Patients Treated with Interferon Beta 1a by 1H-NMR Spectroscopy.

Lorefice L, Murgia F, Fenu G, Frau J, Coghe G, Murru MR, Tranquilli S, Visconti A, Marrosu MG, Atzori L, Cocco E.

Neurotherapeutics. 2019 Feb 28. doi: 10.1007/s13311-019-00721-8. [Epub ahead of print]

PMID:
30820880
2.

Correction to: The Italian multiple sclerosis register.

Trojano M, Bergamaschi R, Amato MP, Comi G, Ghezzi A, Lepore V, Marrosu MG, Mosconi P, Patti F, Ponzio M, Zaratin P, Battaglia MA; Italian Multiple Sclerosis Register Centers Group.

Neurol Sci. 2019 Apr;40(4):907. doi: 10.1007/s10072-019-03772-z.

PMID:
30815752
3.

Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis.

Bandres-Ciga S, Noyce AJ, Hemani G, Nicolas A, Calvo A, Mora G; ITALSGEN Consortium; International ALS Genomics Consortium, Tienari PJ, Stone DJ, Nalls MA, Singleton AB, Chiò A, Traynor BJ.

Ann Neurol. 2019 Apr;85(4):470-481. doi: 10.1002/ana.25431. Epub 2019 Mar 13.

PMID:
30723964
4.

Performance in daily activities, cognitive impairment and perception in multiple sclerosis patients and their caregivers.

Fenu G, Fronza M, Lorefice L, Arru M, Coghe G, Frau J, Marrosu MG, Cocco E.

BMC Neurol. 2018 Dec 19;18(1):212. doi: 10.1186/s12883-018-1224-z.

5.

The Italian multiple sclerosis register.

Trojano M, Bergamaschi R, Amato MP, Comi G, Ghezzi A, Lepore V, Marrosu MG, Mosconi P, Patti F, Ponzio M, Zaratin P, Battaglia MA; Italian Multiple Sclerosis Register Centers Group.

Neurol Sci. 2019 Jan;40(1):155-165. doi: 10.1007/s10072-018-3610-0. Epub 2018 Nov 13. Erratum in: Neurol Sci. 2019 Apr;40(4):907.

6.

Assessing the burden of vascular risk factors on brain atrophy in multiple sclerosis: A case- control MRI study.

Lorefice L, Frau J, Coghe G, Pitzalis R, Gessa I, Contu F, Barracciu MA, Marrosu MG, Cocco E, Fenu G.

Mult Scler Relat Disord. 2019 Jan;27:74-78. doi: 10.1016/j.msard.2018.10.011. Epub 2018 Oct 16.

PMID:
30343253
7.

Quantifying gait impairment in individuals affected by Charcot-Marie-Tooth disease: the usefulness of gait profile score and gait variable score.

Coghe G, Pau M, Mamusa E, Pisano C, Corona F, Pilloni G, Porta M, Marrosu G, Vannelli A, Frau J, Lorefice L, Fenu G, Marrosu MG, Cocco E.

Disabil Rehabil. 2018 Oct 18:1-6. doi: 10.1080/09638288.2018.1506946. [Epub ahead of print]

PMID:
30334469
8.

A multicentric pharmacovigilance study: collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients.

Gugliandolo A, Longo F, Marrosu MG, Mancardi GL, Gandoglia I, Melis M, Lo Giudice F, Bramanti P, Mazzon E.

Ther Clin Risk Manag. 2018 Sep 26;14:1765-1788. doi: 10.2147/TCRM.S174864. eCollection 2018.

9.

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.

Trojano M, Butzkueven H, Kappos L, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S; Tysabri® Observational Program (TOP) Investigators.

Mult Scler Relat Disord. 2018 Aug;24:11-19. doi: 10.1016/j.msard.2018.04.020. Epub 2018 May 2.

10.

Does focal inflammation have an impact on cognition in multiple sclerosis? An MRI study.

Fenu G, Arru M, Lorefice L, Frau J, Coghe G, Fronza M, Loi L, Barracciu MA, Marrosu MG, Cocco E.

Mult Scler Relat Disord. 2018 Jul;23:83-87. doi: 10.1016/j.msard.2018.05.012. Epub 2018 May 16.

PMID:
29800885
11.

A cross-sectional and longitudinal study evaluating brain volumes, RNFL, and cognitive functions in MS patients and healthy controls.

Frau J, Fenu G, Signori A, Coghe G, Lorefice L, Barracciu MA, Sechi V, Cabras F, Badas M, Marrosu MG, Cocco E.

BMC Neurol. 2018 May 11;18(1):67. doi: 10.1186/s12883-018-1065-9.

12.

Pregnancy planning and outcomes in patients with multiple sclerosis after mitoxantrone therapy: a monocentre assessment.

Frau J, Coghe G, Casanova P, Sardu C, Lorefice L, Fenu G, Marrosu MG, Cocco E.

Eur J Neurol. 2018 Aug;25(8):1063-1068. doi: 10.1111/ene.13650. Epub 2018 Apr 25.

PMID:
29611885
13.

Fatigue, as measured using the Modified Fatigue Impact Scale, is a predictor of processing speed improvement induced by exercise in patients with multiple sclerosis: data from a randomized controlled trial.

Coghe G, Corona F, Marongiu E, Fenu G, Frau J, Lorefice L, Crisafulli A, Galli M, Concu A, Marrosu MG, Pau M, Cocco E.

J Neurol. 2018 Jun;265(6):1328-1333. doi: 10.1007/s00415-018-8836-5. Epub 2018 Mar 24.

PMID:
29574556
14.

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.

Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, Dominov JA, Kenna BJ, Nalls MA, Keagle P, Rivera AM, van Rheenen W, Murphy NA, van Vugt JJFA, Geiger JT, Van der Spek RA, Pliner HA, Shankaracharya, Smith BN, Marangi G, Topp SD, Abramzon Y, Gkazi AS, Eicher JD, Kenna A; ITALSGEN Consortium, Mora G, Calvo A, Mazzini L, Riva N, Mandrioli J, Caponnetto C, Battistini S, Volanti P, La Bella V, Conforti FL, Borghero G, Messina S, Simone IL, Trojsi F, Salvi F, Logullo FO, D'Alfonso S, Corrado L, Capasso M, Ferrucci L; Genomic Translation for ALS Care (GTAC) Consortium, Moreno CAM, Kamalakaran S, Goldstein DB; ALS Sequencing Consortium, Gitler AD, Harris T, Myers RM; NYGC ALS Consortium, Phatnani H, Musunuri RL, Evani US, Abhyankar A, Zody MC; Answer ALS Foundation, Kaye J, Finkbeiner S, Wyman SK, LeNail A, Lima L, Fraenkel E, Svendsen CN, Thompson LM, Van Eyk JE, Berry JD, Miller TM, Kolb SJ, Cudkowicz M, Baxi E; Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium, Benatar M, Taylor JP, Rampersaud E, Wu G, Wuu J; SLAGEN Consortium, Lauria G, Verde F, Fogh I, Tiloca C, Comi GP, Sorarù G, Cereda C; French ALS Consortium, Corcia P, Laaksovirta H, Myllykangas L, Jansson L, Valori M, Ealing J, Hamdalla H, Rollinson S, Pickering-Brown S, Orrell RW, Sidle KC, Malaspina A, Hardy J, Singleton AB, Johnson JO, Arepalli S, Sapp PC, McKenna-Yasek D, Polak M, Asress S, Al-Sarraj S, King A, Troakes C, Vance C, de Belleroche J, Baas F, Ten Asbroek ALMA, Muñoz-Blanco JL, Hernandez DG, Ding J, Gibbs JR, Scholz SW, Floeter MK, Campbell RH, Landi F, Bowser R, Pulst SM, Ravits JM, MacGowan DJL, Kirby J, Pioro EP, Pamphlett R, Broach J, Gerhard G, Dunckley TL, Brady CB, Kowall NW, Troncoso JC, Le Ber I, Mouzat K, Lumbroso S, Heiman-Patterson TD, Kamel F, Van Den Bosch L, Baloh RH, Strom TM, Meitinger T, Shatunov A, Van Eijk KR, de Carvalho M, Kooyman M, Middelkoop B, Moisse M, McLaughlin RL, Van Es MA, Weber M, Boylan KB, Van Blitterswijk M, Rademakers R, Morrison KE, Basak AN, Mora JS, Drory VE, Shaw PJ, Turner MR, Talbot K, Hardiman O, Williams KL, Fifita JA, Nicholson GA, Blair IP, Rouleau GA, Esteban-Pérez J, García-Redondo A, Al-Chalabi A; Project MinE ALS Sequencing Consortium, Rogaeva E, Zinman L, Ostrow LW, Maragakis NJ, Rothstein JD, Simmons Z, Cooper-Knock J, Brice A, Goutman SA, Feldman EL, Gibson SB, Taroni F, Ratti A, Gellera C, Van Damme P, Robberecht W, Fratta P, Sabatelli M, Lunetta C, Ludolph AC, Andersen PM, Weishaupt JH, Camu W, Trojanowski JQ, Van Deerlin VM, Brown RH Jr, van den Berg LH, Veldink JH, Harms MB, Glass JD, Stone DJ, Tienari P, Silani V, Chiò A, Shaw CE, Traynor BJ, Landers JE.

Neuron. 2018 Mar 21;97(6):1268-1283.e6. doi: 10.1016/j.neuron.2018.02.027.

15.

Adult brain volume in multiple sclerosis: The impact of paediatric onset.

Fenu G, Lorefice L, Loi L, Sechi V, Contu F, Coghe G, Frau J, Spinicci G, Barracciu MA, Marrosu MG, Cocco E.

Mult Scler Relat Disord. 2018 Apr;21:103-107. doi: 10.1016/j.msard.2018.03.004. Epub 2018 Mar 6.

PMID:
29544192
16.

Autoimmune comorbidities in multiple sclerosis: what is the influence on brain volumes? A case-control MRI study.

Lorefice L, Fenu G, Pitzalis R, Scalas G, Frau J, Coghe G, Musu L, Sechi V, Barracciu MA, Marrosu MG, Cocco E.

J Neurol. 2018 May;265(5):1096-1101. doi: 10.1007/s00415-018-8811-1. Epub 2018 Mar 5.

PMID:
29508133
17.

Exploring cognitive motor interference in multiple sclerosis by the visual Stroop test.

Coghe G, Pilloni G, Zucca E, Porta M, Corona F, Frau J, Fenu G, Lorefice L, Marrosu MG, Pau M, Cocco E.

Mult Scler Relat Disord. 2018 May;22:8-11. doi: 10.1016/j.msard.2018.02.026. Epub 2018 Feb 24.

PMID:
29501850
18.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.

Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Patti F, Solaro C, Bellantonio P, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018 Mar 6;90(10):e823-e831. doi: 10.1212/WNL.0000000000005067. Epub 2018 Feb 7.

PMID:
29438046
19.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.

Portaccio E, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Solaro C, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018 Mar 6;90(10):e832-e839. doi: 10.1212/WNL.0000000000005068. Epub 2018 Feb 7.

PMID:
29438041
20.

Cognition in multiple sclerosis: Between cognitive reserve and brain volume.

Fenu G, Lorefice L, Arru M, Sechi V, Loi L, Contu F, Cabras F, Coghe G, Frau J, Fronza M, Sbrescia G, Lai V, Boi M, Mallus S, Murru S, Porcu A, Barracciu MA, Marrosu MG, Cocco E.

J Neurol Sci. 2018 Mar 15;386:19-22. doi: 10.1016/j.jns.2018.01.011. Epub 2018 Jan 10.

PMID:
29406960
21.

The impact of visible and invisible symptoms on employment status, work and social functioning in Multiple Sclerosis.

Lorefice L, Fenu G, Frau J, Coghe G, Marrosu MG, Cocco E.

Work. 2018;60(2):263-270. doi: 10.3233/WOR-182682.

PMID:
29400690
22.

Pulse steroid therapy in multiple sclerosis and mood changes: An exploratory prospective study.

Lorefice L, Fenu G, Fois M, Frau J, Coghe G, Marrosu MG, Cocco E.

Mult Scler Relat Disord. 2018 Feb;20:104-108. doi: 10.1016/j.msard.2018.01.012. Epub 2018 Jan 31.

PMID:
29360061
23.

Correction to: Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach.

Amato MP, Bertolotto A, Brunelli R, Cavalla P, Goretti B, Marrosu MG, Patti F, Pozzilli C, Provinciali L, Rizzo N, Strobelt N, Tedeschi G, Trojano M, Comi G.

Neurol Sci. 2018 Feb;39(2):395. doi: 10.1007/s10072-017-3226-9.

PMID:
29280018
24.

Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?

Frau J, Villar LM, Sardu C, Secci MA, Schirru L, Ferraro D, Coghe G, Lorefice L, Fenu G, Bedin R, Sola P, Marrosu MG, Cocco E.

J Neurol. 2018 Feb;265(2):424-430. doi: 10.1007/s00415-017-8716-4. Epub 2017 Dec 22.

PMID:
29273846
25.

Long-term follow-up more than 10 years after HSCT: a monocentric experience.

Frau J, Carai M, Coghe G, Fenu G, Lorefice L, La Nasa G, Mamusa E, Vacca A, Marrosu MG, Cocco E.

J Neurol. 2018 Feb;265(2):410-416. doi: 10.1007/s00415-017-8718-2. Epub 2017 Dec 21.

PMID:
29270686
26.

PML in a person with multiple sclerosis: Is teriflunomide the felon?

Lorefice L, Fenu G, Gerevini S, Frau J, Coghe G, Barracciu MA, Contu F, Marrosu MG, Cocco E.

Neurology. 2018 Jan 9;90(2):83-85. doi: 10.1212/WNL.0000000000004804. Epub 2017 Dec 6. No abstract available.

PMID:
29212829
27.

Brain volume in early MS patients with and without IgG oligoclonal bands in CSF.

Fenu G, Lorefice L, Sechi V, Loi L, Contu F, Cabras F, Coghe G, Frau J, Secci MA, Melis C, Schirru L, Costa G, Melas V, Arru M, Barracciu MA, Marrosu MG, Cocco E.

Mult Scler Relat Disord. 2018 Jan;19:55-58. doi: 10.1016/j.msard.2017.11.005. Epub 2017 Nov 8.

PMID:
29132035
28.

Multiple sclerosis and HLA genotypes: A possible influence on brain atrophy.

Lorefice L, Fenu G, Sardu C, Frau J, Coghe G, Costa G, Schirru L, Secci MA, Sechi V, Barracciu MA, Marrosu MG, Cocco E.

Mult Scler. 2019 Jan;25(1):23-30. doi: 10.1177/1352458517739989. Epub 2017 Nov 7.

PMID:
29111883
29.

'Timed up and go' and brain atrophy: a preliminary MRI study to assess functional mobility performance in multiple sclerosis.

Lorefice L, Coghe G, Fenu G, Porta M, Pilloni G, Frau J, Corona F, Sechi V, Barracciu MA, Marrosu MG, Pau M, Cocco E.

J Neurol. 2017 Nov;264(11):2201-2204. doi: 10.1007/s00415-017-8612-y. Epub 2017 Sep 11.

PMID:
28894919
30.

Smoothness of gait detects early alterations of walking in persons with multiple sclerosis without disability.

Pau M, Mandaresu S, Pilloni G, Porta M, Coghe G, Marrosu MG, Cocco E.

Gait Posture. 2017 Oct;58:307-309. doi: 10.1016/j.gaitpost.2017.08.023. Epub 2017 Aug 24.

PMID:
28858779
31.

Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach.

Amato MP, Bertolotto A, Brunelli R, Cavalla P, Goretti B, Marrosu MG, Patti F, Pozzilli C, Provinciali L, Rizzo N, Strobelt N, Tedeschi G, Trojano M, Comi G.

Neurol Sci. 2017 Oct;38(10):1849-1858. doi: 10.1007/s10072-017-3081-8. Epub 2017 Aug 2. Erratum in: Neurol Sci. 2017 Dec 26;:.

PMID:
28770366
32.

Localized pigmentation disorder after subcutaneous pegylated interferon beta-1a injection.

Coghe G, Atzori L, Frau J, Fenu G, Lorefice L, Marrosu MG, Cocco E.

Mult Scler. 2018 Feb;24(2):231-233. doi: 10.1177/1352458517708465. Epub 2017 Jul 28.

PMID:
28752785
33.

Metabolomic analysis identifies altered metabolic pathways in Multiple Sclerosis.

Poddighe S, Murgia F, Lorefice L, Liggi S, Cocco E, Marrosu MG, Atzori L.

Int J Biochem Cell Biol. 2017 Dec;93:148-155. doi: 10.1016/j.biocel.2017.07.004. Epub 2017 Jul 16.

PMID:
28720279
34.

The burden of multiple sclerosis and patients' coping strategies.

Lorefice L, Fenu G, Frau J, Coghe G, Marrosu MG, Cocco E.

BMJ Support Palliat Care. 2018 Mar;8(1):38-40. doi: 10.1136/bmjspcare-2017-001324. Epub 2017 Jun 24.

PMID:
28647714
35.

Are static and functional balance abilities related in individuals with Multiple Sclerosis?

Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice L, Marrosu MG, Cocco E.

Mult Scler Relat Disord. 2017 Jul;15:1-6. doi: 10.1016/j.msard.2017.04.002. Epub 2017 Apr 11.

PMID:
28641764
36.

Overexpression of the Cytokine BAFF and Autoimmunity Risk.

Steri M, Orrù V, Idda ML, Pitzalis M, Pala M, Zara I, Sidore C, Faà V, Floris M, Deiana M, Asunis I, Porcu E, Mulas A, Piras MG, Lobina M, Lai S, Marongiu M, Serra V, Marongiu M, Sole G, Busonero F, Maschio A, Cusano R, Cuccuru G, Deidda F, Poddie F, Farina G, Dei M, Virdis F, Olla S, Satta MA, Pani M, Delitala A, Cocco E, Frau J, Coghe G, Lorefice L, Fenu G, Ferrigno P, Ban M, Barizzone N, Leone M, Guerini FR, Piga M, Firinu D, Kockum I, Lima Bomfim I, Olsson T, Alfredsson L, Suarez A, Carreira PE, Castillo-Palma MJ, Marcus JH, Congia M, Angius A, Melis M, Gonzalez A, Alarcón Riquelme ME, da Silva BM, Marchini M, Danieli MG, Del Giacco S, Mathieu A, Pani A, Montgomery SB, Rosati G, Hillert J, Sawcer S, D'Alfonso S, Todd JA, Novembre J, Abecasis GR, Whalen MB, Marrosu MG, Meloni A, Sanna S, Gorospe M, Schlessinger D, Fiorillo E, Zoledziewska M, Cucca F.

N Engl J Med. 2017 Apr 27;376(17):1615-1626. doi: 10.1056/NEJMoa1610528.

37.

Erratum to: Charcot-Marie-Tooth disease: genetic subtypes in the Sardinian population.

Lorefice L, Murru MR, Coghe G, Fenu G, Corongiu D, Frau J, Tranquilli S, Tacconi P, Vannelli A, Marrosu G, Mamusa E, Cocco E, Marrosu MG.

Neurol Sci. 2017 Jun;38(6):1027. doi: 10.1007/s10072-017-2944-3. No abstract available.

PMID:
28389936
38.

Charcot-Marie-Tooth disease: genetic subtypes in the Sardinian population.

Lorefice L, Murru MR, Coghe G, Fenu G, Corongiu D, Frau J, Tranquilli S, Tacconi P, Vannelli A, Marrosu G, Mamusa E, Cocco E, Marrosu MG.

Neurol Sci. 2017 Jun;38(6):1019-1025. doi: 10.1007/s10072-017-2905-x. Epub 2017 Mar 13. Erratum in: Neurol Sci. 2017 Jun;38(6):1027.

PMID:
28286897
39.

Quantitative assessment of the effects of 6 months of adapted physical activity on gait in people with multiple sclerosis: a randomized controlled trial.

Pau M, Corona F, Coghe G, Marongiu E, Loi A, Crisafulli A, Concu A, Galli M, Marrosu MG, Cocco E.

Disabil Rehabil. 2018 Jan;40(2):144-151. doi: 10.1080/09638288.2016.1244291. Epub 2017 Jan 13.

PMID:
28084119
40.

Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs.

Degli Esposti L, Piccinni C, Sangiorgi D, Perrone V, Aledda L, Marrosu MG, Lombardo F.

Neurol Sci. 2017 Apr;38(4):589-594. doi: 10.1007/s10072-016-2806-4. Epub 2017 Jan 11.

PMID:
28078563
41.

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.

42.

Clinical assessment of gait in individuals with multiple sclerosis using wearable inertial sensors: Comparison with patient-based measure.

Pau M, Caggiari S, Mura A, Corona F, Leban B, Coghe G, Lorefice L, Marrosu MG, Cocco E.

Mult Scler Relat Disord. 2016 Nov;10:187-191. doi: 10.1016/j.msard.2016.10.007. Epub 2016 Oct 27.

PMID:
27919488
43.

The Required Coefficient of Friction for evaluating gait alterations in people with Multiple Sclerosis during gait.

Pacifici I, Galli M, Kleiner AF, Corona F, Coghe G, Marongiu E, Loi A, Crisafulli A, Cocco E, Marrosu MG, Pau M.

Mult Scler Relat Disord. 2016 Nov;10:174-178. doi: 10.1016/j.msard.2016.10.004. Epub 2016 Oct 24.

PMID:
27919485
44.

Muscle elastography: a new imaging technique for multiple sclerosis spasticity measurement.

Illomei G, Spinicci G, Locci E, Marrosu MG.

Neurol Sci. 2017 Mar;38(3):433-439. doi: 10.1007/s10072-016-2780-x. Epub 2016 Nov 30.

PMID:
27904961
45.

Effects of Six Months Training on Physical Capacity and Metaboreflex Activity in Patients with Multiple Sclerosis.

Magnani S, Olla S, Pau M, Palazzolo G, Tocco F, Doneddu A, Marcelli M, Loi A, Corona F, Corona F, Coghe G, Marrosu MG, Concu A, Cocco E, Marongiu E, Crisafulli A.

Front Physiol. 2016 Nov 14;7:531. eCollection 2016.

46.

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators.

Neurology. 2016 Nov 8;87(19):1985-1992. Epub 2016 Oct 12.

47.

Is Geo-Environmental Exposure a Risk Factor for Multiple Sclerosis? A Population-Based Cross-Sectional Study in South-Western Sardinia.

Monti MC, Guido D, Montomoli C, Sardu C, Sanna A, Pretti S, Lorefice L, Marrosu MG, Valera P, Cocco E.

PLoS One. 2016 Sep 26;11(9):e0163313. doi: 10.1371/journal.pone.0163313. eCollection 2016.

48.

Combining HLA-DRB1-DQB1 and Mycobacterium Avium Subspecies Paratubercolosis (MAP) antibodies in Sardinian multiple sclerosis patients: associated or independent risk factors?

Frau J, Cossu D, Sardu C, Mameli G, Coghe G, Lorefice L, Fenu G, Tranquilli S, Sechi LA, Marrosu MG, Cocco E.

BMC Neurol. 2016 Aug 23;16(1):148. doi: 10.1186/s12883-016-0669-1.

49.

Perception of risk and shared decision making process in multiple sclerosis.

Cocco E, Caoci A, Lorefice L, Marrosu MG.

Expert Rev Neurother. 2017 Feb;17(2):173-180. doi: 10.1080/14737175.2016.1217155. Epub 2016 Aug 4. Review.

PMID:
27467681
50.

History of multiple sclerosis in 2 successive pregnancies: A French and Italian cohort.

Benoit A, Durand-Dubief F, Amato MP, Portaccio E, Casey R, Roggerone S, Androdias G, Gignoux L, Ionescu I, Marrosu MG, Cocco E, Ghezzi A, Annovazzi P, Trojano M, Simone M, Marignier R, Confavreux C, Vukusic S.

Neurology. 2016 Sep 27;87(13):1360-7. doi: 10.1212/WNL.0000000000003036. Epub 2016 Jul 27.

PMID:
27466470

Supplemental Content

Loading ...
Support Center